Y Richard Wang

Summary

Affiliation: Temple University
Country: USA

Publications

  1. doi request reprint Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Ann Surg 251:51-8. 2010
  2. ncbi request reprint Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelpia, PA 19140, USA
    Arch Intern Med 167:141-7. 2007
  3. ncbi request reprint Lack of effect of guideline changes on hypertension control for patients with diabetes in the U.S., 1995-2005
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
    Diabetes Care 30:49-52. 2007
  4. doi request reprint Trends of Heller myotomy hospitalizations for achalasia in the United States, 1993-2005: effect of surgery volume on perioperative outcomes
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Am J Gastroenterol 103:2454-64. 2008
  5. doi request reprint Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in symptomatic patients referred for gastric emptying scintigraphy
    Daniel W Cassilly
    Gastrointestinal Section, Department of Medicine, Temple University, Philadelphia, PA 19140, USA
    Digestion 78:144-51. 2008
  6. ncbi request reprint High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial
    J Sanford Schwartz
    Department of Medicine, Leonard Davis Institute of Health Economics, Wharton School, Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
    Am J Manag Care 9:417-24. 2003
  7. ncbi request reprint The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
    Patricia M Danzon
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104 6218, USA
    Health Econ 14:269-92. 2005
  8. ncbi request reprint Price competition in the Chinese pharmaceutical market
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals 1800 Concord Pike, Wilmington, DE, 19850 5437, USA
    Int J Health Care Finance Econ 6:119-29. 2006
  9. ncbi request reprint The prevalence of diagnosed cutaneous manifestations during ambulatory diabetes visits in the United States, 1998-2002
    Y Richard Wang
    Public Policy Department, Astra Zeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Dermatology 212:229-34. 2006
  10. ncbi request reprint The quantity and quality of worldwide new drug introductions, 1982-2003
    Henry G Grabowski
    Department of Economics, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:452-60. 2006

Collaborators

Detail Information

Publications12

  1. doi request reprint Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Ann Surg 251:51-8. 2010
    ..The purpose of this study was to quantify the time trends of hospitalizations and operations for PUD in the United States (US) since 1993...
  2. ncbi request reprint Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelpia, PA 19140, USA
    Arch Intern Med 167:141-7. 2007
    ..Hypertension guidelines in the United States tend to have more aggressive treatment recommendations than those in European countries...
  3. ncbi request reprint Lack of effect of guideline changes on hypertension control for patients with diabetes in the U.S., 1995-2005
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
    Diabetes Care 30:49-52. 2007
    ..S. using patients without diabetes as the control group for the time trend...
  4. doi request reprint Trends of Heller myotomy hospitalizations for achalasia in the United States, 1993-2005: effect of surgery volume on perioperative outcomes
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Am J Gastroenterol 103:2454-64. 2008
    ..We aimed to study the trends of Heller myotomy and the relationship between surgery volume and perioperative outcomes...
  5. doi request reprint Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in symptomatic patients referred for gastric emptying scintigraphy
    Daniel W Cassilly
    Gastrointestinal Section, Department of Medicine, Temple University, Philadelphia, PA 19140, USA
    Digestion 78:144-51. 2008
    ..The aim of this study was to correlate symptoms using the GCSI with delayed gastric emptying (DGE) in symptomatic patients referred for gastric emptying scintigraphy (GES)...
  6. ncbi request reprint High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial
    J Sanford Schwartz
    Department of Medicine, Leonard Davis Institute of Health Economics, Wharton School, Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
    Am J Manag Care 9:417-24. 2003
    ..Angiotensin-converting enzyme (ACE) inhibitors reduce heart failure death and hospitalization. Prescribed doses often are lower than randomized clinical trial (RCT) targets and practice guideline recommendations...
  7. ncbi request reprint The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
    Patricia M Danzon
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104 6218, USA
    Health Econ 14:269-92. 2005
    ..Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative...
  8. ncbi request reprint Price competition in the Chinese pharmaceutical market
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals 1800 Concord Pike, Wilmington, DE, 19850 5437, USA
    Int J Health Care Finance Econ 6:119-29. 2006
    ..Policy changes that encourage bioequivalent local products and accelerate global product approvals will enhance price competition in China...
  9. ncbi request reprint The prevalence of diagnosed cutaneous manifestations during ambulatory diabetes visits in the United States, 1998-2002
    Y Richard Wang
    Public Policy Department, Astra Zeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Dermatology 212:229-34. 2006
    ..The prevalence of diabetes has been rapidly increasing. Previous reports indicated that diabetics are prone to certain cutaneous diseases...
  10. ncbi request reprint The quantity and quality of worldwide new drug introductions, 1982-2003
    Henry G Grabowski
    Department of Economics, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:452-60. 2006
    ..S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch...
  11. ncbi request reprint Screening and treatment of hypercholesterolemia for prevention of coronary heart disease
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850, USA
    Manag Care Interface 19:25-9. 2006
    ..Drug therapy recommendation also decreasedwith greater NCEP risk. Despite improvements, underscreening and undertreatment of hypercholesterolemia persists in outpatient visits...
  12. ncbi request reprint Difference in the use of preventive services between fee-for-service plans and HMOs: is more better?
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 9:293-301. 2003
    ....